School of Health and Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA, UK; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QQ, UK.
School of Health and Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA, UK; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QQ, UK.
Drug Alcohol Depend. 2022 Mar 1;232:109263. doi: 10.1016/j.drugalcdep.2021.109263. Epub 2022 Jan 31.
COVID-19 has likely affected the delivery of interventions to prevent blood-borne viruses (BBVs) among people who inject drugs (PWID). We examined the impact of the first wave of COVID-19 in Scotland on: 1) needle and syringe provision (NSP), 2) opioid agonist therapy (OAT) and 3) BBV testing.
An interrupted time series study design; 23rd March 2020 (date of the first 'lockdown') was chosen as the key date.
The number of HIV tests and HCV tests in drug services/prisons, and the number of needles/syringes (N/S) distributed decreased by 94% (RR=0.062, 95% CI 0.041-0.094, p < 0.001), 95% (RR=0.049, 95% CI 0.034-0.069, p < 0.001) and 18% (RR = 0.816, 95% CI 0.750-0.887, p < 0.001), respectively, immediately after lockdown. Post-lockdown, an increasing trend was observed relating to the number of N/S distributed (0.6%; RR = 1.006, 95% CI 1.001-1.012, p = 0.015), HIV tests (12.1%; RR = 1.121, 95% CI 1.092-1.152, p < 0.001) and HCV tests (13.2%; RR = 1.132, 95 CI 1.106-1.158, p < 0.001). Trends relating to the total amount of methadone prescribed remained stable, but a decreasing trend in the number of prescriptions (2.4%; RR = 0.976, 95% CI 0.959-0.993, p = 0.006) and an increasing trend in the quantity prescribed per prescription (2.8%; RR = 1.028, 95% CI 1.013-1.042, p < 0.001) was observed post-lockdown.
COVID-19 impacted the delivery of BBV prevention services for PWID in Scotland. While there is evidence of service recovery; further effort is likely required to return some intervention coverage to pre-pandemic levels in the context of subsequent waves of COVID-19.
COVID-19 可能影响了为注射吸毒者(PWID)提供预防血源性病毒(BBV)的干预措施。我们研究了 COVID-19 第一波在苏格兰对以下方面的影响:1)针具和注射器供应(NSP),2)阿片类药物替代治疗(OAT)和 3)BBV 检测。
采用中断时间序列研究设计;选择 2020 年 3 月 23 日(首次“封锁”日期)作为关键日期。
药物服务/监狱中的 HIV 检测和 HCV 检测数量以及针头/注射器(N/S)的分发数量分别减少了 94%(RR=0.062,95%CI 0.041-0.094,p<0.001),95%(RR=0.049,95%CI 0.034-0.069,p<0.001)和 18%(RR=0.816,95%CI 0.750-0.887,p<0.001),封锁后立即下降。封锁后,与 N/S 分发数量相关的呈上升趋势(0.6%;RR=1.006,95%CI 1.001-1.012,p=0.015),HIV 检测(12.1%;RR=1.121,95%CI 1.092-1.152,p<0.001)和 HCV 检测(13.2%;RR=1.132,95 CI 1.106-1.158,p<0.001)。与美沙酮规定总量有关的趋势保持稳定,但规定的数量呈下降趋势(2.4%;RR=0.976,95%CI 0.959-0.993,p=0.006),规定的剂量呈上升趋势(2.8%;RR=1.028,95%CI 1.013-1.042,p<0.001)。
COVID-19 对苏格兰 PWID 的 BBV 预防服务的提供产生了影响。尽管有证据表明服务已经恢复;在 COVID-19 的后续浪潮中,可能需要进一步努力才能使一些干预措施的覆盖率恢复到大流行前的水平。